ClinicalTrials.gov
public full text
Public Domain
Bortezomib in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well bortezomib works in treating patients with relapsed or refractory cutaneous T-cell lymphoma.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia#1009414
- Bortezomib in Treating Patients With Mantle Cell Lymphoma#1112297
- Cancer Treatment Followed by Surgery for Early Stage Non-small Cell Lung Cancer#890546
- Bortezomib in Treating Patients With Metastatic Kidney Cancer#880773
- Bortezomib in Treating Patients With Recurrent Glioma#1101644
Record · ID 992656
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive